Medical Disclaimer: This content is for informational purposes only. It does not constitute medical advice. Consult a licensed medical professional before starting any weight loss program. Individual results vary.
Finding the best tirzepatide and semaglutide clinics in Texas is harder than it looks in 2026. More providers entered the GLP-1 space over the past two years. Regulations shifted. Quality standards vary widely across clinics in Dallas, Fort Worth, Austin, Plano, and beyond. This guide tells you what actually separates a solid program from a risky one, what questions to ask any Texas clinic, and how the programs work.
Texas has one of the highest adult obesity rates in the country. The CDC reports that over 35% of Texas adults live with obesity, and that number has climbed steadily for two decades. Diet and exercise work for some people. But for many, the biology works against them. Appetite hormones, metabolic rate, and blood sugar regulation all play a role.
GLP-1 medications changed the math. Semaglutide and tirzepatide don’t replace lifestyle changes. They support the body’s natural fullness and appetite signals so those changes actually stick. The clinical trial data behind these medications is some of the strongest in obesity medicine. And Texas clinics in cities like Dallas, Fort Worth, The Woodlands, and Austin have made access easier with virtual programs and local offices.
But more access also means more variation in quality. And in 2026, the regulatory picture got more complicated.
This is the part most clinics don’t explain clearly. The rules around GLP-1 medications changed significantly in 2025 and 2026. If you’re searching for compounded semaglutide or compounded tirzepatide in Texas, you need to understand what happened.
The FDA declared the semaglutide shortage resolved in February 2025. Tirzepatide’s shortage was officially resolved in late 2024. Both of those decisions ended the primary legal basis for large-scale compounding under 503B outsourcing facility rules.
Then, on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely. The agency cited no clinical need for outsourcing facilities to compound these drugs from bulk substances. The public comment period runs through June 29, 2026, before a final determination is made.
This doesn’t mean all GLP-1 access has ended. Under federal law, 503A patient-specific compounding by state-licensed pharmacies remains a legal pathway. That means a licensed pharmacy can still compound medication for an individual patient based on a valid prescription. But large-scale bulk compounding for mass distribution has been significantly curtailed.
Before starting a GLP-1 program in Texas, ask these questions directly:
Any reputable Texas provider should answer these without hesitation. Vague answers are a warning sign.
The quality gap between GLP-1 programs in Texas is significant. Some clinics offer real clinical depth. Others run semi-automated platforms that barely qualify as medical oversight. Here’s how to tell the difference.
A legitimate weight loss program puts a licensed provider in your corner. That means a physician or nurse practitioner reviews your health history, screens for contraindications, and follows your progress over time. Some online platforms use algorithmic questionnaires with minimal human review. That’s a different experience than working with a real clinical team.
Look for programs with nurse-led care and physician oversight built in at every step, not just at sign-up.
The source of your medication matters. Ask where your medication is prepared and what quality standards that pharmacy follows. Licensed compounding pharmacies operate under state board oversight, follow sterility protocols, and conduct potency testing. Not every pharmacy operating in this space meets those standards. The FDA has issued warning letters to compounders for sterility lapses and fill weight discrepancies. Ask your clinic directly about their pharmacy partner’s compliance history.
A price that seems too low usually means something is missing. Good programs include provider consultations, progress monitoring, dosing adjustments, and ongoing support. All of that takes real clinical time. Before you commit, get a clear breakdown of what your monthly program fee actually covers.
Semaglutide is a GLP-1 receptor agonist. Originally developed for type 2 diabetes under the brand name Ozempic, it earned FDA approval for chronic weight management under the brand name Wegovy. In a 68-week clinical trial studying Wegovy at 2.4 mg, patients without diabetes lost an average of 15% of body weight when paired with diet and lifestyle changes. The control group, which used diet and exercise alone, lost 2.4% on average.
Semaglutide mimics a natural gut hormone called GLP-1. Here’s what it does in your body:
It works best alongside a calorie-reduced diet and regular physical activity.
Eligibility always depends on a licensed provider’s review of your individual health history. Generally, candidates include:
Your provider makes the final call. No reputable clinic should skip that step.
Tirzepatide is the newer option in the GLP-1 space. It targets two receptors, GLP-1 and GIP, instead of one. That dual action gives it a different metabolic profile than semaglutide. In the SURMOUNT-1 clinical trial, patients on the highest tirzepatide dose lost an average of 20% of body weight over 72 weeks when paired with lifestyle changes. The control group using diet and exercise alone averaged 3.1%.
Tirzepatide activates GLP-1 and GIP receptors at the same time. Practically, that means:
The once-weekly injection schedule keeps things manageable. Most patients self-inject at home after a brief training session.
Both medications support meaningful weight loss. The right choice depends on your health history, goals, and your provider’s recommendation.
| Factor | Semaglutide | Tirzepatide |
| Receptor targets | GLP-1 only | GLP-1 + GIP |
| Avg. weight loss (trial data) | ~15% over 68 weeks | ~20% over 72 weeks |
| Dosing schedule | Once weekly | Once weekly |
| Brand-name version | Wegovy | Zepbound |
| InjectCo program pricing | From $249/month | From $425/month |
Neither medication replaces lifestyle change. Both require physician oversight and a structured program to produce lasting results.
Access has been one of the biggest barriers to quality GLP-1 care in Texas. Many virtual-only platforms offer no local support. Some local clinics can’t handle the virtual side. InjectCo does both. They serve patients across eight Texas locations and via telehealth statewide.
Dallas and Fort Worth represent two of the largest markets for GLP-1 programs in Texas. InjectCo’s Dallas clinic sits at 2520 N Carroll Ave, serving patients throughout the city and nearby neighborhoods. The Fort Worth area is served through the Plano location at 5964 W Parker Rd, Suite 107, inside Phenix Suites of Willow Bend. Patients in both markets can also complete everything virtually through InjectCo’s telehealth platform.
North Dallas suburbs have seen some of the strongest demand for physician-supervised weight loss in the state. Plano patients can visit 5964 W Parker Rd, Suite 107, with access to the same physician-directed program available across all InjectCo locations. Colleyville patients work with Jen Adams, RN BSN, a cadaver-certified injector with over 13 years of experience, and Shelby, an RN and aesthetic specialist, serving the northeast Tarrant County corridor.
Denton County and Ellis County aren’t usually the first places people think of for medical weight loss. But the demand is real and growing. InjectCo’s Argyle clinic is located inside Cloud 9 at 2660 FM 407 E in Bartonville. The Waxahachie location is at 102 Professional Pl, Suite 101. Both bring physician oversight and the same clinical standards as InjectCo’s larger market locations.
The Woodlands location at 250 Ed English Dr, Suite 3D, in Shenandoah covers the growing Houston-area corridor north of the city. Austin patients can visit 8312 Burnet Rd, Suite 107, in one of Texas’s fastest-growing metros. Both markets benefit from InjectCo’s virtual option for patients who can’t come in during early program stages.
The process is fully virtual to start. Here’s how it works step by step:
No in-person visit is required to get started. Patients can call (817) 533-7676 or book online. Spanish-speaking patients can reach InjectCo at (469) 804-9964.
InjectCo has treated over 50,000 patients across injectable, laser, and wellness services. Their clinical team carries 75+ combined years of experience, and they hold a perfect 5-star rating across all Texas locations. Programs are 100% nurse-led with physician oversight on every prescription.
Choosing a GLP-1 clinic in Texas comes down to one question: is there a real clinical team behind the program? Physician supervision, licensed pharmacy sourcing, and transparent pricing separate reliable programs from the ones cutting corners.
InjectCo offers both semaglutide and tirzepatide programs for Texas patients, backed by licensed nurse injectors and physician oversight at every step.
Ready to start? Visit their compounded semaglutide program page for program details, or check out their tirzepatide delivery program to learn more about the dual-action option.
Both programs are available virtually statewide and in person at InjectCo’s eight Texas locations: Dallas, Fort Worth, Plano, Colleyville, Argyle, The Woodlands, Waxahachie, and Austin.
Financing is available through CareCredit and Cherry, with 0% APR options for qualifying patients.
What makes a GLP-1 clinic in Texas legitimate in 2026? Legitimate clinics have licensed physicians reviewing every prescription. They use state-licensed pharmacy partners and provide ongoing monitoring. They answer questions about their pharmacy sourcing directly. Vague answers about where medication comes from or who reviews your case are red flags.
Are compounded semaglutide and tirzepatide still available in Texas? 503A patient-specific compounding by state-licensed pharmacies remains a legal pathway. The FDA ended large-scale 503B bulk compounding after resolving the drug shortage declarations for both medications. Ask any Texas clinic directly about the legal basis for their compounding setup and which pharmacy they use.
How much do GLP-1 programs cost in Texas? Program pricing varies widely. InjectCo’s semaglutide program starts at $249/month and tirzepatide starts at $425/month. Both include provider consultations, monitoring, and dosing support. CareCredit and Cherry financing options are available.
Do I need in-person visits to get a GLP-1 program in Texas? No. InjectCo’s program starts fully online. Patients who prefer in-person care can visit any of InjectCo’s eight Texas locations. Same-day appointments are available, and clinic hours run 8 AM to 8 PM, seven days a week.
How long before I see results on a GLP-1 program? Most patients notice appetite changes in the first two to four weeks. Meaningful weight changes typically show up around weeks 8 to 16. Clinical trial data shows average weight losses of 15% to 20% over 68 to 72 weeks, when paired with diet and exercise changes.
What’s the difference between semaglutide and tirzepatide? Semaglutide works on one receptor (GLP-1). Tirzepatide works on two (GLP-1 and GIP). Clinical trials show tirzepatide tends to produce greater average weight loss. Your provider reviews your health profile and recommends which program fits your situation.
| Keyword | Type | Placement |
| Best tirzepatide clinics in Texas | Primary | Title, intro, H2 |
| Best semaglutide clinics in Texas | Primary | Title, intro, body |
| Compounded GLP-1 Texas | Primary | H2, body x2 |
| Tirzepatide Texas | Secondary | Body x4 |
| Semaglutide Texas | Secondary | Body x4 |
| GLP-1 weight loss program Texas | Secondary | Body x3 |
| Physician-supervised weight loss Texas | Long-tail | Body x2 |
| Medical weight loss Dallas Fort Worth | Long-tail | City section |
| Tirzepatide vs semaglutide Texas | Long-tail | Comparison table |
| Online semaglutide prescription Texas | Long-tail | Body |
| Compounded tirzepatide 2026 Texas | Long-tail | Regulatory section |
